Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 76

1.

Evidence for reducing cancer-specific mortality due to screening for breast cancer in Europe: A systematic review.

Zielonke N, Gini A, Jansen EEL, Anttila A, Segnan N, Ponti A, Veerus P, de Koning HJ, van Ravesteyn NT, Heijnsdijk EAM; EU-TOPIA consortium.

Eur J Cancer. 2020 Jan 10. pii: S0959-8049(19)30863-9. doi: 10.1016/j.ejca.2019.12.010. [Epub ahead of print] Review.

PMID:
31932175
2.

All-cause mortality versus cancer-specific mortality as outcome in cancer screening trials: A review and modeling study.

Heijnsdijk EAM, Csanádi M, Gini A, Ten Haaf K, Bendes R, Anttila A, Senore C, de Koning HJ.

Cancer Med. 2019 Oct;8(13):6127-6138. doi: 10.1002/cam4.2476. Epub 2019 Aug 18.

3.

The role of modelling in the policy decision making process for cancer screening: example of prostate specific antigen screening.

Getaneh AM, Heijnsdijk EA, de Koning HJ.

Public Health Res Pract. 2019 Jul 31;29(2). pii: 2921912. doi: 10.17061/phrp2921912.

4.

MRI versus mammography for breast cancer screening in women with familial risk (FaMRIsc): a multicentre, randomised, controlled trial.

Saadatmand S, Geuzinge HA, Rutgers EJT, Mann RM, de Roy van Zuidewijn DBW, Zonderland HM, Tollenaar RAEM, Lobbes MBI, Ausems MGEM, van 't Riet M, Hooning MJ, Mares-Engelberts I, Luiten EJT, Heijnsdijk EAM, Verhoef C, Karssemeijer N, Oosterwijk JC, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MMA; FaMRIsc study group.

Lancet Oncol. 2019 Aug;20(8):1136-1147. doi: 10.1016/S1470-2045(19)30275-X. Epub 2019 Jun 17.

PMID:
31221620
5.

Evaluating Parameter Uncertainty in a Simulation Model of Cancer Using Emulators.

de Carvalho TM, Heijnsdijk EAM, Coffeng L, de Koning HJ.

Med Decis Making. 2019 May;39(4):405-413. doi: 10.1177/0272989X19837631. Epub 2019 Jun 10. Erratum in: Med Decis Making. 2019 Nov;39(8):898.

PMID:
31179833
6.

The Impact of Design and Performance in Prostate-Specific Antigen Screening: Differences Between ERSPC Centers.

Heijnsdijk EAM, Adolfsson J, Auvinen A, Roobol MJ, Hugosson J, de Koning HJ.

Eur Urol. 2019 Sep;76(3):276-279. doi: 10.1016/j.eururo.2019.04.007. Epub 2019 Apr 26.

PMID:
31031050
7.

Informed decision-making based on a leaflet in the context of prostate cancer screening.

Dierks T, Heijnsdijk EAM, Korfage IJ, Roobol MJ, de Koning HJ.

Patient Educ Couns. 2019 Aug;102(8):1483-1489. doi: 10.1016/j.pec.2019.03.009. Epub 2019 Apr 13.

PMID:
31014933
8.

A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer.

Hugosson J, Roobol MJ, Månsson M, Tammela TLJ, Zappa M, Nelen V, Kwiatkowski M, Lujan M, Carlsson SV, Talala KM, Lilja H, Denis LJ, Recker F, Paez A, Puliti D, Villers A, Rebillard X, Kilpeläinen TP, Stenman UH, Godtman RA, Stinesen Kollberg K, Moss SM, Kujala P, Taari K, Huber A, van der Kwast T, Heijnsdijk EA, Bangma C, De Koning HJ, Schröder FH, Auvinen A; ERSPC investigators.

Eur Urol. 2019 Jul;76(1):43-51. doi: 10.1016/j.eururo.2019.02.009. Epub 2019 Feb 26.

PMID:
30824296
9.

Key indicators of organized cancer screening programs: Results from a Delphi study.

Csanádi M, de Kok IM, Heijnsdijk EA, Anttila A, Heinävaara S, Pitter JG, Széles G, Ivanuš U, Priaulx J, Veerus P, Senore C, Koning HJ, Vokó Z.

J Med Screen. 2019 Sep;26(3):120-126. doi: 10.1177/0969141318820362. Epub 2019 Jan 8. No abstract available.

PMID:
30621498
10.

Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer.

Heijnsdijk EAM, Nieboer D, Garg T, Lansdorp-Vogelaar I, de Koning HJ, Nielsen ME.

BJU Int. 2019 Feb;123(2):307-312. doi: 10.1111/bju.14502. Epub 2018 Aug 27.

11.

Simulating the Impact of Risk-Based Screening and Treatment on Breast Cancer Outcomes with MISCAN-Fadia.

van den Broek JJ, van Ravesteyn NT, Heijnsdijk EA, de Koning HJ.

Med Decis Making. 2018 Apr;38(1_suppl):54S-65S. doi: 10.1177/0272989X17711928.

12.

Detection and interval cancer rates during the transition from screen-film to digital mammography in population-based screening.

Sankatsing VDV, Fracheboud J, de Munck L, Broeders MJM, van Ravesteyn NT, Heijnsdijk EAM, Verbeek ALM, Otten JDM, Pijnappel RM, Siesling S, de Koning HJ; National Evaluation Team for Breast cancer screening, NETB.

BMC Cancer. 2018 Mar 5;18(1):256. doi: 10.1186/s12885-018-4122-2.

13.

Comparative effectiveness of prostate cancer screening between the ages of 55 and 69 years followed by active surveillance.

de Carvalho TM, Heijnsdijk EAM, de Koning HJ.

Cancer. 2018 Feb 1;124(3):507-513. doi: 10.1002/cncr.31141. Epub 2017 Dec 12.

14.

The efficacy of prostate-specific antigen screening: Impact of key components in the ERSPC and PLCO trials.

de Koning HJ, Gulati R, Moss SM, Hugosson J, Pinsky PF, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, de Carvalho TM, Feuer EJ, Tsodikov A, Mariotto AB, Heijnsdijk EAM, Etzioni R.

Cancer. 2018 Mar 15;124(6):1197-1206. doi: 10.1002/cncr.31178. Epub 2017 Dec 6.

15.

Summary statement on screening for prostate cancer in Europe.

Heijnsdijk EAM, Bangma CH, Borràs JM, de Carvalho TM, Castells X, Eklund M, Espinàs JA, Graefen M, Grönberg H, Lansdorp-Vogelaar I, Leeuwen PJV, Nelen V, Recker F, Roobol MJ, Vandenbulcke P, de Koning HJ.

Int J Cancer. 2018 Feb 15;142(4):741-746. doi: 10.1002/ijc.31102. Epub 2017 Oct 25.

16.

Reconciling the Effects of Screening on Prostate Cancer Mortality in the ERSPC and PLCO Trials.

Tsodikov A, Gulati R, Heijnsdijk EAM, Pinsky PF, Moss SM, Qiu S, de Carvalho TM, Hugosson J, Berg CD, Auvinen A, Andriole GL, Roobol MJ, Crawford ED, Nelen V, Kwiatkowski M, Zappa M, Luján M, Villers A, Feuer EJ, de Koning HJ, Mariotto AB, Etzioni R.

Ann Intern Med. 2017 Oct 3;167(7):449-455. doi: 10.7326/M16-2586. Epub 2017 Sep 5.

17.

Authors' reply to: "Questionable method for estimating the influence of mammography screening on breast cancer mortality in the Netherlands".

Sankatsing VDV, van Ravesteyn NT, Heijnsdijk EAM, de Koning HJ.

Int J Cancer. 2017 Oct 15;141(8):1709-1710. doi: 10.1002/ijc.30873. Epub 2017 Jul 21. No abstract available.

18.

The effect of population-based mammography screening in Dutch municipalities on breast cancer mortality: 20 years of follow-up.

Sankatsing VDV, van Ravesteyn NT, Heijnsdijk EAM, Looman CWN, van Luijt PA, Fracheboud J, den Heeten GJ, Broeders MJM, de Koning HJ.

Int J Cancer. 2017 Aug 15;141(4):671-677. doi: 10.1002/ijc.30754.

19.

Is prostate cancer different in black men? Answers from 3 natural history models.

Tsodikov A, Gulati R, de Carvalho TM, Heijnsdijk EAM, Hunter-Merrill RA, Mariotto AB, de Koning HJ, Etzioni R.

Cancer. 2017 Jun 15;123(12):2312-2319. doi: 10.1002/cncr.30687. Epub 2017 Apr 24.

20.

When should active surveillance for prostate cancer stop if no progression is detected?

de Carvalho TM, Heijnsdijk EAM, de Koning HJ.

Prostate. 2017 Jun;77(9):962-969. doi: 10.1002/pros.23352. Epub 2017 Apr 17.

PMID:
28419541
21.

Cost-effectiveness of the Norwegian breast cancer screening program.

van Luijt PA, Heijnsdijk EA, de Koning HJ.

Int J Cancer. 2017 Feb 15;140(4):833-840. doi: 10.1002/ijc.30513. Epub 2016 Nov 23.

22.

Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.

Carlsson SV, de Carvalho TM, Roobol MJ, Hugosson J, Auvinen A, Kwiatkowski M, Villers A, Zappa M, Nelen V, Páez A, Eastham JA, Lilja H, de Koning HJ, Vickers AJ, Heijnsdijk EA.

Cancer. 2016 Nov 15;122(21):3386-3393. doi: 10.1002/cncr.30192. Epub 2016 Jul 26.

23.

Breast cancer incidence trends in Norway and estimates of overdiagnosis.

van Luijt PA, Heijnsdijk EA, van Ravesteyn NT, Hofvind S, de Koning HJ.

J Med Screen. 2017 Jun;24(2):83-91. doi: 10.1177/0969141316668379. Epub 2016 Oct 17.

PMID:
27754936
24.

Mammographic screening in BRCA1 mutation carriers postponed until age 40: Evaluation of benefits, costs and radiation risks using models.

Obdeijn IM, Heijnsdijk EA, Hunink MG, Tilanus-Linthorst MM, de Koning HJ.

Eur J Cancer. 2016 Aug;63:135-42. doi: 10.1016/j.ejca.2016.05.012. Epub 2016 Jun 15.

PMID:
27318001
25.

Estimating the risks and benefits of active surveillance protocols for prostate cancer: a microsimulation study.

de Carvalho TM, Heijnsdijk EA, de Koning HJ.

BJU Int. 2017 Apr;119(4):560-566. doi: 10.1111/bju.13542. Epub 2016 Jun 26.

26.

The distribution of ductal carcinoma in situ (DCIS) grade in 4232 women and its impact on overdiagnosis in breast cancer screening.

van Luijt PA, Heijnsdijk EA, Fracheboud J, Overbeek LI, Broeders MJ, Wesseling J, den Heeten GJ, de Koning HJ.

Breast Cancer Res. 2016 May 10;18(1):47. doi: 10.1186/s13058-016-0705-5.

27.

The role of pre-invasive disease in overdiagnosis: A microsimulation study comparing mass screening for breast cancer and cervical cancer.

van Luijt PA, Rozemeijer K, Naber SK, Heijnsdijk EA, van Rosmalen J, van Ballegooijen M, de Koning HJ.

J Med Screen. 2016 Dec;23(4):210-216. Epub 2016 Apr 11.

PMID:
27068430
28.

The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.

Heijnsdijk EA, Denham D, de Koning HJ.

Value Health. 2016 Mar-Apr;19(2):153-7. doi: 10.1016/j.jval.2015.12.002. Epub 2016 Jan 14.

29.

Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies.

Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, Alagoz O, Kerlikowske K, Tosteson AN, Near AM, Hoeffken A, Chang Y, Heijnsdijk EA, Chisholm G, Huang X, Huang H, Ergun MA, Gangnon R, Sprague BL, Plevritis S, Feuer E, de Koning HJ, Cronin KA.

Ann Intern Med. 2016 Feb 16;164(4):215-25. doi: 10.7326/M15-1536. Epub 2016 Jan 12.

30.

Estimating the individual benefit of immediate treatment or active surveillance for prostate cancer after screen-detection in older (65+) men.

de Carvalho TM, Heijnsdijk EA, de Koning HJ.

Int J Cancer. 2016 May 15;138(10):2522-8. doi: 10.1002/ijc.29976. Epub 2016 Feb 1.

31.

Swiss Medical Board Mammography screening predictions for Switzerland: importance of time-periods.

de Koning HJ, Heijnsdijk EA.

J Med Screen. 2015 Dec;22(4):201-6. doi: 10.1177/0969141315586639. Epub 2015 May 27.

PMID:
26018779
32.

Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis.

van Ravesteyn NT, Stout NK, Schechter CB, Heijnsdijk EA, Alagoz O, Trentham-Dietz A, Mandelblatt JS, de Koning HJ.

J Natl Cancer Inst. 2015 May 6;107(7). pii: djv103. doi: 10.1093/jnci/djv103. Print 2015 Jul.

33.

Cost-effectiveness of digital mammography screening before the age of 50 in The Netherlands.

Sankatsing VD, Heijnsdijk EA, van Luijt PA, van Ravesteyn NT, Fracheboud J, de Koning HJ.

Int J Cancer. 2015 Oct 15;137(8):1990-9. doi: 10.1002/ijc.29572. Epub 2015 May 8.

34.

Transition from film to digital mammography: impact for breast cancer screening through the national breast and cervical cancer early detection program.

van Ravesteyn NT, van Lier L, Schechter CB, Ekwueme DU, Royalty J, Miller JW, Near AM, Cronin KA, Heijnsdijk EA, Mandelblatt JS, de Koning HJ.

Am J Prev Med. 2015 May;48(5):535-42. doi: 10.1016/j.amepre.2014.11.010.

35.

Response.

Heijnsdijk EA, de Koning HJ.

J Natl Cancer Inst. 2015 Apr 16;107(6):djv111. doi: 10.1093/jnci/djv111. Print 2015 Jun. No abstract available.

PMID:
25888717
36.

Survival benefit in women with BRCA1 mutation or familial risk in the MRI screening study (MRISC).

Saadatmand S, Obdeijn IM, Rutgers EJ, Oosterwijk JC, Tollenaar RA, Woldringh GH, Bergers E, Verhoef C, Heijnsdijk EA, Hooning MJ, de Koning HJ, Tilanus-Linthorst MM.

Int J Cancer. 2015 Oct 1;137(7):1729-38. doi: 10.1002/ijc.29534. Epub 2015 Apr 17.

37.

Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.

Heijnsdijk EA, de Carvalho TM, Auvinen A, Zappa M, Nelen V, Kwiatkowski M, Villers A, Páez A, Moss SM, Tammela TL, Recker F, Denis L, Carlsson SV, Wever EM, Bangma CH, Schröder FH, Roobol MJ, Hugosson J, de Koning HJ.

J Natl Cancer Inst. 2014 Dec 13;107(1):366. doi: 10.1093/jnci/dju366. Print 2015 Jan.

38.

The effects of population-based mammography screening starting between age 40 and 50 in the presence of adjuvant systemic therapy.

de Gelder R, Heijnsdijk EA, Fracheboud J, Draisma G, de Koning HJ.

Int J Cancer. 2015 Jul 1;137(1):165-72. doi: 10.1002/ijc.29364. Epub 2014 Dec 13.

39.

Predicting the stage shift as a result of breast cancer screening in low- and middle-income countries: a proof of concept.

Zelle SG, Baltussen R, Otten JD, Heijnsdijk EA, van Schoor G, Broeders MJ.

J Med Screen. 2015 Mar;22(1):8-19. doi: 10.1177/0969141314559956. Epub 2014 Nov 21.

PMID:
25416699
40.

The Oncotyrol Prostate Cancer Outcome and Policy Model - How Latent Prevalence Affects the Benefit-Harm Balance of Screening.

Mühlberger N, Heijnsdijk EA, Kurzthaler C, Iskandar R, Krahn MD, Bremner K, Oberaigner W, Klocker H, Horninger W, Conrads-Frank A, Sroczynski G, Siebert U.

Value Health. 2014 Nov;17(7):A559. doi: 10.1016/j.jval.2014.08.1843. Epub 2014 Oct 26. No abstract available.

41.

Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.

Munoz D, Near AM, van Ravesteyn NT, Lee SJ, Schechter CB, Alagoz O, Berry DA, Burnside ES, Chang Y, Chisholm G, de Koning HJ, Ali Ergun M, Heijnsdijk EA, Huang H, Stout NK, Sprague BL, Trentham-Dietz A, Mandelblatt JS, Plevritis SK.

J Natl Cancer Inst. 2014 Sep 24;106(11). pii: dju289. doi: 10.1093/jnci/dju289. Print 2014 Nov.

42.

Screening for prostate cancer in the US? Reduce the harms and keep the benefit.

de Carvalho TM, Heijnsdijk EA, de Koning HJ.

Int J Cancer. 2015 Apr 1;136(7):1600-7. doi: 10.1002/ijc.29136. Epub 2014 Sep 1.

43.

Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits.

Lansdorp-Vogelaar I, Gulati R, Mariotto AB, Schechter CB, de Carvalho TM, Knudsen AB, van Ravesteyn NT, Heijnsdijk EA, Pabiniak C, van Ballegooijen M, Rutter CM, Kuntz KM, Feuer EJ, Etzioni R, de Koning HJ, Zauber AG, Mandelblatt JS.

Ann Intern Med. 2014 Jul 15;161(2):104-12. doi: 10.7326/M13-2867.

44.

The influence of disease risk on the optimal time interval between screens for the early detection of cancer: a mathematical approach.

O'Mahony JF, van Rosmalen J, Mushkudiani NA, Goudsmit FW, Eijkemans MJ, Heijnsdijk EA, Steyerberg EW, Habbema JD.

Med Decis Making. 2015 Feb;35(2):183-95. doi: 10.1177/0272989X14528380. Epub 2014 Apr 16.

PMID:
24739535
45.

Empirical estimates of prostate cancer overdiagnosis by age and prostate-specific antigen.

Vickers AJ, Sjoberg DD, Ulmert D, Vertosick E, Roobol MJ, Thompson I, Heijnsdijk EA, De Koning H, Atoria-Swartz C, Scardino PT, Lilja H.

BMC Med. 2014 Feb 11;12:26. doi: 10.1186/1741-7015-12-26.

46.

Cost-effectiveness of screening women with familial risk for breast cancer with magnetic resonance imaging.

Saadatmand S, Tilanus-Linthorst MM, Rutgers EJ, Hoogerbrugge N, Oosterwijk JC, Tollenaar RA, Hooning M, Loo CE, Obdeijn IM, Heijnsdijk EA, de Koning HJ.

J Natl Cancer Inst. 2013 Sep 4;105(17):1314-21. doi: 10.1093/jnci/djt203. Epub 2013 Aug 12.

PMID:
23940285
47.

Nation-wide data on screening performance during the transition to digital mammography: observations in 6 million screens.

van Luijt PA, Fracheboud J, Heijnsdijk EA, den Heeten GJ, de Koning HJ; National Evaluation Team for Breast Cancer Screening in Netherlands Study Group (NETB).

Eur J Cancer. 2013 Nov;49(16):3517-25. doi: 10.1016/j.ejca.2013.06.020. Epub 2013 Jul 17.

48.

Treatment of local-regional prostate cancer detected by PSA screening: benefits and harms according to prognostic factors.

Wever EM, Heijnsdijk EA, Draisma G, Bangma CH, Roobol MJ, Schröder FH, de Koning HJ.

Br J Cancer. 2013 May 28;108(10):1971-7. doi: 10.1038/bjc.2013.198. Epub 2013 May 14.

49.

Collaborative modeling of the impact of obesity on race-specific breast cancer incidence and mortality.

Chang Y, Schechter CB, van Ravesteyn NT, Near AM, Heijnsdijk EA, Adams-Campbell L, Levy D, de Koning HJ, Mandelblatt JS.

Breast Cancer Res Treat. 2012 Dec;136(3):823-35. doi: 10.1007/s10549-012-2274-3. Epub 2012 Oct 27.

50.

Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial.

Saadatmand S, Rutgers EJ, Tollenaar RA, Zonderland HM, Ausems MG, Keymeulen KB, Schlooz-Vries MS, Koppert LB, Heijnsdijk EA, Seynaeve C, Verhoef C, Oosterwijk JC, Obdeijn IM, de Koning HJ, Tilanus-Linthorst MM.

BMC Cancer. 2012 Oct 2;12:440. doi: 10.1186/1471-2407-12-440.

Supplemental Content

Loading ...
Support Center